Standard and variant Philadelphia translocation in a CML patient with different sensitivity to imatinib therapy [0.03%]
慢性粒细胞白血病患者Ph染色体及变异型Ph染色体对伊马替尼治疗敏感性差异的一例报告
Stefania Aliano,Gabriella Cirmena,Giuseppina Fugazza et al.
Stefania Aliano et al.
Most chronic myeloid leukemia (CML) patients show the Philadelphia chromosome (Ph) arising from the reciprocal t(9;22), but 5-10% present variants of this translocation involving different breakpoints besides 9q34 and 22q11. WE REPORT THE N...
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities [0.03%]
来那度胺单药及与阿糖胞苷、柔红霉素和依托泊苷联用治疗染色体5异常的高危骨髓增生异常综合征和急性髓系白血病
M Dennis,D Culligan,D Karamitros et al.
M Dennis et al.
Patients with high risk myelodysplasia (HR-MDS) and acute myeloid leukaemia (AML) with chromosomal changes involving deletion of the long arm of chromosome 5 (del5q), especially with complex karyotype, rarely have a durable response to comb...
Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentation [0.03%]
慢性粒细胞白血病继发急变的初诊病例一例报告
Shokichi Tsukamoto,Satoshi Ota,Chikako Ohwada et al.
Shokichi Tsukamoto et al.
Extramedullary blast crisis of chronic myelogenous leukemia (CML) is defined as the development of extramedullary disease caused by the infiltration of blasts regardless of proliferation of blasts in the bone marrow. The onset of extramedul...
Prognostic impact of JAK2V617F mutation in myelodysplatic syndromes: A matched case control study [0.03%]
jak2v617f突变对骨髓增生异常综合征预后影响的病例对照研究
Benoit de Renzis,Veronique Mansat-De Mas,Eric Wattel et al.
Benoit de Renzis et al.
While in RARS-T, JAK2V617F mutation is common and associated with good prognosis, the clinical and prognostic impact of this mutation in other MDS is unknown. We collected data from 132 non-RARS-T MDS with known JAK2V617F mutation status. J...
Sigrun Thorsteinsdottir,Ole Weis Bjerrum,Hans Carl Hasselbalch
Sigrun Thorsteinsdottir
The concurrence of myeloproliferative neoplasms (MPNs) and multiple sclerosis (MS) is unusual. We report five patients from a localized geographic area in Denmark with both MS and MPN; all the patients were diagnosed with MPNs in the years ...
Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy [0.03%]
伊马替尼治疗慢性髓性白血病患者后瘦素的变化：靶向治疗的新兴作用
Stefania Mariani,Sabrina Basciani,Fiorina Giona et al.
Stefania Mariani et al.
We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal ran...
Lymphocyte recovery and infused CD34+ cells dose: Effect on the evolution after stem cell autotransplantation [0.03%]
淋巴细胞恢复及输注CD34＋细胞剂量对自体干细胞移植后转归的影响
Esperanza Romero Fernández,Guillermo Montalbán Bravo,Rosario Arrieta Gallastegui et al.
Esperanza Romero Fernández et al.
Background and objective: The number of infused CD34+cells (CD34+i) has been associated with absolute lymphocyte count (ALC) and the outcome undergoing autologous hematopoietic stem cell transplantation (HSCT) in patients...
Kinetics of del(7q) driven leukemogenesis in a patient with JAK2 V617F and TET2 mutated chronic myeloproliferative neoplasm [0.03%]
JAK2 V617F和TET2变异的慢性骨髓增殖性肿瘤患者del（7q）诱导白血病的动态过程
Laura Laine Herborg,Line Nederby,Eigil Kjeldsen et al.
Laura Laine Herborg et al.
Chronic myeloid neoplasms have susceptibility to transform into acute myeloid leukemia due to attainment of additional molecular lesions. We here describe the kinetics of a del(7q) driven leukemogenesis in a patient with multiple TET2 mutat...
Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors: A single centre's experience [0.03%]
二代酪氨酸激酶抑制剂治疗后高危慢性髓性白血病患者异基因干细胞移植安全有效：单中心经验报告
Anne-Louise Latif,Grant McQuaker,Anne Parker et al.
Anne-Louise Latif et al.
Most patients now receiving a haematopoietic stem cell transplant (HSCT) for chronic myeloid leukaemia (CML) have been treated with first and second line TKIs pre-HSCT, raising concerns that these patients will have more resistant disease a...
Valproic acid for the treatment of low-risk myelodysplastic syndromes: A case report and a review of the literature [0.03%]
用于低危骨髓增生异常综合征治疗的丙戊酸钠：一例报告及文献复习
Antonella Poloni,Benedetta Costantini,Marianna Mariani et al.
Antonella Poloni et al.
Myelodysplastic syndromes are heterogeneous myeloid neoplasms ranging from indolent conditions with a near-normal life expectancy to forms approaching acute myeloid leukemia. Here we report a 51-year-old woman with depression and severe obe...